Clinical Trials Browser

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT02890355 2026-03-05

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

123 enrolled 15 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04233866 2026-03-02

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Phase 2 Active not recruiting

176 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05014776 2026-02-24

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

17 enrolled 8 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT04331041 2026-02-17

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Phase 2 Active not recruiting

42 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06015659 2026-02-09

ZN-c3 + Gemcitabine in Pancreatic Cancer

Phase 2 Active not recruiting

12 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03601923 2026-01-28

Niraparib in Patients With Pancreatic Cancer

Phase 2 Active not recruiting

32 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05026905 2026-01-20

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

66 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06168812 2026-01-15

A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

Phase 2 Active not recruiting

29 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03104439 2026-01-12

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

Phase 2 Active not recruiting

84 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04241276 2026-01-07

STARPAC2

Phase 2 Active not recruiting

170 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04820179 2026-01-07

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

Phase 2 Active not recruiting

30 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

30 enrolled

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT05945823 2025-12-29

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase 2 Active not recruiting

53 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT04390399 2025-12-15

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

328 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02451982 2025-12-03

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Phase 2 Active not recruiting

76 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06519097 2025-11-13

Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

Phase 2 Active not recruiting

4 enrolled

Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

NCT01972919 2025-10-27

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

23 enrolled 8 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04940286 2025-10-08

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Phase 2 Active not recruiting

13 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03563248 2025-10-01

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Phase 2 Active not recruiting

168 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05481476 2025-09-04

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

32 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01088789 2025-08-26

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

Phase 2 Active not recruiting

71 enrolled 13 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT04111172 2025-08-22

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

Phase 2 Active not recruiting

48 enrolled

Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05604560 2025-07-23

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Phase 2 Active not recruiting

25 enrolled

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT04594772 2025-07-02

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

Phase 2 Active not recruiting

32 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04098081 2025-07-01

1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

Phase 2 Active not recruiting

15 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03856658 2025-06-17

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

Phase 2 Active not recruiting

14 enrolled

Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT02340117 2025-05-30

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

28 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05632328 2025-05-20

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Phase 2 Active not recruiting

24 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Phase 2 Active not recruiting

39 enrolled

GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06390059 2025-04-30

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Active not recruiting

84 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02912949 2025-04-29

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Phase 2 Active not recruiting

250 enrolled 1 FDA

GastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

NCT05915351 2025-04-16

Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)

Phase 2 Active not recruiting

28 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01585805 2025-03-11

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

88 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06766019 2025-01-09

Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer

Phase 2 Active not recruiting

47 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06119217 2024-12-04

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Phase 2 Active not recruiting

194 enrolled

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT06094140 2024-12-03

NEO-IMPACT

Phase 2 Active not recruiting

20 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

Phase 2 Active not recruiting

350 enrolled

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05659914 2024-10-18